{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["17"],"submitter":["Kelm M"],"pubmed_abstract":["<h4>Introduction</h4>Blinatumomab (BLN) is a bispecific T-cell engager that has revolutionized the treatment of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), significantly improving outcomes in both adults and children. By simultaneously binding to CD19 on B cells and CD3 on T cells, BLN triggers target cell-dependent T-cell activation, resulting in the cytolysis of CD19<sup>+</sup> BCP-ALL cells. Despite the remarkable clinical advancements achieved with BLN, the immunological mechanisms underlying treatment response or failure remain poorly characterized. γδ T cells are attractive candidates for adoptive T-cell therapy due to potent cytotoxicity, capacity to present antigens, broad lysis of different tumor entities, and low alloreactivity. Because γδ T cells can also be redire"],"journal":["Frontiers in immunology"],"pagination":["1739493"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12920462"],"repository":["biostudies-literature"],"pubmed_title":["Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from &lt;i&gt;in vitro&lt;/i&gt; assays."],"pmcid":["PMC12920462"],"pubmed_authors":["Bendig S","Peters C","Kabelitz D","Nasr N","Laqua A","Janssen O","Trautmann H","Baldus CD","Chitadze G","Scheffold A","Wesch D","Kelm M","Lustig M","Oberg HH","Bruggemann M","Valerius T"],"additional_accession":[]},"is_claimable":false,"name":"Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from &lt;i&gt;in vitro&lt;/i&gt; assays.","description":"<h4>Introduction</h4>Blinatumomab (BLN) is a bispecific T-cell engager that has revolutionized the treatment of B-cell precursor acute lymphoblastic leukemia (BCP-ALL), significantly improving outcomes in both adults and children. By simultaneously binding to CD19 on B cells and CD3 on T cells, BLN triggers target cell-dependent T-cell activation, resulting in the cytolysis of CD19<sup>+</sup> BCP-ALL cells. Despite the remarkable clinical advancements achieved with BLN, the immunological mechanisms underlying treatment response or failure remain poorly characterized. γδ T cells are attractive candidates for adoptive T-cell therapy due to potent cytotoxicity, capacity to present antigens, broad lysis of different tumor entities, and low alloreactivity. Because γδ T cells can also be redire","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026","modification":"2026-07-16T18:06:56.547Z","creation":"2026-07-09T11:10:43.196Z"},"accession":"S-EPMC12920462","cross_references":{"pubmed":["41727470"],"doi":["10.3389/fimmu.2026.1739493"]}}